Northwest Biosensor Consulting, LLC

Quality binding analysis by SPR

Selected Publications

Hanes V, Born T, Chow V, Zhang N, Howard M, Schulz A, Markus R. Amgen, Inc., Thousand Oaks, CA.; Amgen, Inc., Seattle, WA. Comparative similarity of ABP 980 and trastuzumab: Results of functional similarity and human pharmacokinetic assessment. San Antonio Breast Cancer Symposium, San Antonio, TX.  December 8 -12, 2015.

Henne, K. R., B. Ason, M. Howard, W. Wang, J. Sun, J. Higbee, J. Tang, K. C. Matsuda, R. Xu, L. Zhou, J. C. Chan, C. King, D. E. Piper, R. R. Ketchem, M. L. Michaels, S. M. Jackson and M. W. Retter. "Anti-Pcsk9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement." J Pharmacol Exp Ther 353, no. 1 (2015): 119-31.

Liu, Z., E. C. Leng, K. Gunasekaran, M. Pentony, M. Shen, M. Howard, J. Stoops, K. Manchulenko, V. Razinkov, H. Liu, W. Fanslow, Z. Hu, N. Sun, H. Hasegawa, R. Clark, I. N. Foltz and W. Yan. "A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism." J Biol Chem 290, no. 12 (2015): 7535-62.

Richard Markus, Primal Kaur, Vincent Chow, Nan Zhang, Teresa Born, Quyen Huynh, Gwen Maher, Jyoti Velayudhan, Monique Howard, Kaz Reynhardt, Theresa Goletz. Results of Functional Testing and Pharmacokinetics comparing ABP 215 to Bevacizumab. J Clin Oncol 33, 2015 (suppl 3; abstr 711); ASCO Gastrointestinal Cancers Symposium, San Francisco, CA. January 15-17, 2015.